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Abstract
Background: Photobiomodulation (PBMT) is a therapy that uses non-ionising forms of light, including low-level
lasers and light-emitting diodes (LEDs) that may be capable of modulating cellular activity. Some biological
processes may also interact with static magnetic fields (sMF), leading to modulatory effects on cells. Previous
studies have verified that the combination of PBMT and sMF (PBMT/sMF) enhances the performance of individuals
during aerobic training programs. The detraining period can cause losses in aerobic capacity. However, there is no
evidence of the existence of any recourse that can decrease the effects of detraining. We aimed to investigate the
effects of PBMT/sMF application during training and detraining to assess the effectiveness of this treatment in
reducing the effects of detraining.
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Methods: Sixty male volunteers were randomly allocated into four groups— participants who received PBMT/sMF
during the training and detraining (PBMT/sMF + PBMT/sMF); participants who received PBMT/sMF during the
training and a placebo in the detraining (PBMT/sMF + Placebo); participants who received a placebo during the
training and PBMT/sMF in the detraining (Placebo+PBMT/sMF); and participants who received a placebo during the
training and detraining (Placebo+Placebo). Participants performed treadmill training over 12 weeks (3 sessions/
week), followed by 4 weeks of detraining. PBMT/sMF was applied using a 12-diode emitter (four 905 nm super-
pulsed lasers, four 875 nm light-emitting diodes (LEDs), four 640 nm LEDs, and a 35 mT magnetic field) at 17 sites
on each lower limb (dosage: 30 J per site). The data were analysed by two-way repeated measures analysis of
variance (ANOVA, time vs experimental group) with post-hoc Bonferroni correction.
Results: The percentage of change in time until exhaustion and in maximum oxygen consumption was higher in
the PBMT/sMF + PBMT/sMF group than in the Placebo+Placebo group at all time-points (p < 0.05). Moreover, the
percentage of decrease in body fat at the 16th week was higher in the PBMT/sMF + PBMT/sMF group than in the
Placebo+Placebo group (p < 0.05).
Conclusions: PBMT/sMF can potentiate the effects of aerobic endurance training and decrease performance loss
after a 4-week detraining period. Thus, it may prove to be an important tool for both amateur and high-
performance athletes as well as people undergoing rehabilitation.
Trial registration: NCT03879226. Trial registered on 18 March 2019.
Keywords: Low-level laser therapy, Light-emitting diode therapy, Phototherapy, Endurance exercise,
Deconditioning
Background
Regular physical activity is recommended for improving
general health, performance enhancement, and the re-
habilitation of chronic diseases [1, 2]. In addition, aer-
obic exercise improves cardiovascular health and
decreases body fat mass [3–7]. However, individuals
often discontinue exercise in response to illness, injury,
or other factors that may alter their capacity for physical
activity, causing a rapid loss of aerobic conditioning that
can be observed after 2–4 weeks [8, 9]. Currently, there
is insufficient evidence to support the ability of any par-
ticular resource or method to decrease the effects of
detraining.
Photobiomodulation therapy (PBMT) is a therapy
that uses non-ionising light sources, such as lasers,
light-emitting diodes (LEDs), and broadband light,
from the visible to the infrared spectrum [10]. PBMT
elicits a nonthermal process where light interacts with
chromophores leading to photophysical and photo-
chemical reactions in different tissues, thereby pro-
moting cell metabolism modulation [11, 12]. PBMT
has been investigated for promoting exercise-related
ergogenic effects [10]. Leal-Junior et al. (2009), Anto-
nialli et al. (2014), and de Paiva et al. (2016) observed
that the use of PBMT with exercise can reduce creat-
ine kinase (CK) activity through its protective effects
on skeletal muscle tissue, allowing for a faster recov-
ery [13–15]. Other studies indicate that PBMT can
decrease blood lactate levels and thus, help to im-
prove performance during exercise [16–18].
Static magnetic fields (sMF) are force fields that are
produced by moving electrical currents that act on other
mobile charges, which can interact with several bio-
logical processes [19, 20], also leading to the modulation
of cellular metabolism [20–22]. Previous studies have re-
ported that the use of sMF in association with PBMT
generates greater effects in cellular metabolism than the
use of PBMT alone [23]. In the clinical context, it has
been demonstrated that the association of PBMT with
sMF (PBMT/sMF) promotes ergogenic effects [18, 24].
Moreover, Miranda et al. (2018) verified that this com-
bination enhances the performance of individuals during
an aerobic training program, increasing the percentage
of change of maximum oxygen consumption (VO2max)
and time until exhaustion after 12 weeks of the train-
ing protocol [25].
To the best of our knowledge, no previous study has in-
vestigated the effects of PBMT/sMF in the detraining or
deconditioning period. However, the effects of PBMT on
the oxidative metabolism of peripheral blood cells (erythro-
cytes, granulocytes, and lymphocytes), leading to an en-
hanced oxygen-carrying ability of blood, was previously
demonstrated in heparinised blood samples [26]. According
to Wasik et al., the partial pressure of oxygen (PO2) and
oxygen saturation (SaO2) increases after PBMT irradiation
[26]. These findings suggest that PBMT could attenuate the
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loss of performance observed during the detraining period
after an aerobic training program through increased oxygen
transportation, and consequently, the ability of muscles to
use it, which is decreased during the detraining period.
Therefore, PBMT/sMF may prove to be an important
tool for both amateur and high-performance athletes as
well as for people in the process of rehabilitation who
discontinue exercise due to illness, injury, or other fac-
tors. With this perspective, we aimed to investigate the
effects of PBMT/sMF during the training and detraining
period in maintaining the benefits acquired in an aerobic
training program.
Methods
The protocol and methods used in this study were
previously published in a peer-reviewed scientific
journal [27].
Design and ethical aspects
A randomised, triple-blind (volunteers, therapists, and
assessors), placebo-controlled clinical trial was per-
formed at the Laboratory of Phototherapy and Innova-
tive Technologies in Health (LaPIT). The study followed
the ethical guidelines of and was approved by the Re-
search Ethics Committee of Nove de Julho University
(protocol number 1781602). The protocol was prospect-
ively registered at ClinicalTrials.org (NCT03879226) by
18 March 2019. The first volunteer was enrolled at 25
March 2019, and all volunteers signed an informed con-
sent form at the time of enrolment in the study.
Subjects and sample size
As no previous studies have assessed the effects of
PBMT/sMF during the detraining period after an aer-
obic training program, the number of participants per
group in the present study was calculated based on a
pilot study, with five volunteers per group, conducted by
our research group to estimate the sample size. A beta
value of 20% and alpha value of 5% were used to calcu-
late the sample size.
The pilot study showed that applying PBMT/sMF
during the detraining period resulted in a time to ex-
haustion (the primary outcome of this study) of
923.60 s (standard deviation, 65.77 s) during the pro-
gressive treadmill test; whereas applying the placebo
during the detraining period resulted in a time to ex-
haustion of 846.82 s (standard deviation, 99.23 s). We
used the Researcher’s Toolkit to calculate the sample
(https://www.dssresearch.com/KnowledgeCenter/toolk-
itcalculators/samplesizecalculators.aspx).
Based on the parameters used to calculate the sample,
we determined that 15 volunteers per group, for a total
of 60 volunteers, was appropriate. Therefore, predicting
a 20% sample loss, up to 72 healthy and physically
inactive male volunteers aged 18–35 years who were stu-
dents at the Nove de Julho University, would be re-
cruited for the study to ensure a final sample size of 60
volunteers. As the PBMT/sMF device used in the study
has no harmful thermal effects, volunteers of all ethnici-
ties were recruited [28].
Patient and public involvement statement
Patients and/or the public were not involved in the de-
sign, recruitment to, and conduct of this study. At the
end of the study, the main results were disseminated to
participants by email.
Eligibility criteria
Inclusion criteria
Healthy men aged 18–35 years from all ethnicities, who
were non-smokers, with no history of a musculoskeletal
injury in the hip and knee regions in the 2 months be-
fore the study, who did not regularly use pharmaco-
logical agents and/or nutritional supplements, and who
completed at least 80% of the study procedures, were in-
cluded in the study.
Exclusion criteria
Volunteers who showed any musculoskeletal injury in
the 2 months before the study, were injured during the
study, regularly used any type of nutritional supplement
or pharmacological agent, or who showed signs and
symptoms of any neurological, metabolic, inflammatory,
pulmonary, oncological, or cardiovascular disease that
may limit the execution of high-intensity exercises, were
excluded from the study.
Randomisation and blinding and experimental groups
In order to avoid selection bias, and to ensure that all in-
dividuals were randomly allocated to any group, bal-
anced block randomisation was performed based on the
primary outcome (time to exhaustion in the progressive
treadmill test) by a researcher who had no contact with
the study subjects or the other researchers involved in
the project.
A researcher programmed the device (PBMT/sMF or
placebo) and was instructed not to inform the volunteers
or other researchers of the type of treatment (PBMT/
sMF or placebo). The sounds and signals emitted from
the device as well as the information displayed on the
screen were identical, regardless of the type of treatment
(PBMT/sMF or placebo), providing the appropriate
blinding of volunteers and therapists. All volunteers used
opaque glasses during the treatments both for safety and
to aid in blinding. Thus, volunteers, evaluators, and ther-
apists were blinded to maintain the triple-blind design.
Randomisation labels were created through the ran-
dom.org website, and a series of sealed, opaque, and
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numbered envelopes were used to ensure confidentiality
and to determine to which experimental group each vol-
unteer was to be allocated. Volunteers were allocated as
described below:
PBMT/sMF + PBMT/sMF: PBMT/sMF before and
after the aerobic training sessions (12 weeks, 3 times a
week) and PBMT/sMF during the detraining period (4
weeks, 3 times a week).
PBMT/sMF + Placebo: PBMT/sMF before and after
the aerobic training sessions (12 weeks, 3 times a week)
and placebo during the detraining period (4 weeks, 3
times a week).
Placebo+PBMT/sMF: Placebo before and after the aer-
obic training sessions (12 weeks, 3 times a week) and
PBMT/sMF during the detraining period (4 weeks, 3
times a week).
Placebo+Placebo: Placebo before and after the aerobic
training sessions (12 weeks, 3 times a week) and placebo
during the detraining period (4 weeks, 3 times a week).
The individuals were subjected to 12 consecutive
weeks of aerobic endurance training on a motorised
treadmill, with 3 training sessions per week on non-
consecutive days.
After the 12-week training period, the volunteers re-
ceived the treatment (either PBMT/sMF or placebo, de-
pending on the group to which they were allocated)
during the 4 weeks (3 times a week) without training.
The evaluations described below were performed be-
fore starting the protocol (baseline) and after 4, 8, and
12 weeks of aerobic endurance training as well as after 4
weeks without training (detraining period) at the 16th
week. A flowchart summarising the procedures of this
study is presented in Fig. 1.
Procedures
Cardiorespiratory evaluation
Ergospirometry is currently the most accurate cardiore-
spiratory fitness test [29]. In this study, we used a pro-
gressive treadmill protocol previously used by our
research group [25, 30–32]. An ergometric treadmill
model Super ATL AQ5, and a gas analyser model
VO2000, which was connected to a microcomputer for
data visualisation and recording were used. The ergos-
pirometry test started with the treadmill set at a 1%
slope, with an initial speed of 3 km/h, which was main-
tained until the end of the 3-min warm-up phase. After
the warm-up phase, the speed was increased by 1 km/h
every minute until a maximum speed of 16 km/h was
reached. The end of the test was defined by the volun-
teers, who were instructed to perform the test until they
reached exhaustion [25, 30–32]. The recovery phase
then began, lasting 3 min at a speed of 6 km/h. During
the test, data on the total time of the exercise (time to
exhaustion), maximum oxygen uptake in absolute and
relative values in relation to body mass (VO2max) were
recorded [25, 30–32]. The chosen parameters represent
those that are most commonly used for this purpose,
Fig. 1 CONSORT flowchart
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and as such, these data were used to assess the perform-
ance of the subjects in the exercise protocol [29].
The entire test was monitored by electrocardiography
and blood pressure measurements. If any abnormal
changes in heart rate or blood pressure were found, or if
the volunteer had any complaint, the test was discontin-
ued, and the volunteer was excluded from the study.
Body composition evaluation
All body composition evaluations were performed by the
same technician (level II of the International Society for
the Advancement of Kineanthropometry - ISAK), using
the procedures established by the ISAK [33]. The height,
body mass, length of body segments, diameters, perime-
ters, and skinfolds of the participants were measured to
assess the muscle mass, adipose mass, residual mass,
bone mass, and epithelial mass [25].
Aerobic training
Aerobic training was performed on a treadmill, with and
without PBMT/sMF, 3 times a week on non-consecutive
days, for 12 weeks. Each training session was supervised
by a certified trainer and lasted 30min. The speed of the
motorised treadmill was tailored to each participant for
every training session. The speed of the treadmill was
varied during the exercise to keep the heart rate of the
volunteers between 85 to 90% of maximum heart rate
[25]; the heart rate of the volunteers was monitored dur-
ing the entire exercise session using a heart rate moni-
tor. The maximum heart rate was determined during the
cardiorespiratory evaluation protocol described above
[25, 31].
The protocol was interrupted when criteria established
by the American Heart Association guidelines were met.
The subjects were also evaluated using the 0–10 Borg
scale, which is a simple method for classifying perceived
exertion, feelings of physical fatigue, or dyspnoea.
Photobiomodulation therapy (PBMT) and static magnetic
fields (sMF)
PBMT/sMF or placebo were applied before and after
each training session, as aforementioned. This irradi-
ation protocol was tested and optimised in a previous
study conducted by our research group [25]. The results
of this study showed that PBMT/sMF before and after
each training session was the most effective in enhancing
the effects of aerobic training [25]. PBMT/sMF was ap-
plied bilaterally using the direct contact method with
light pressure on the skin at different sites, namely nine
sites on the knee extensor muscles (Fig. 2a), six sites on
the knee flexor muscles, and two sites on the plantar
flexor muscles (Fig. 2b).
To apply PBMT/sMF, a 12-diode cluster was used, in-
cluding four 905 nm laser diodes (12.5W peak power of
each diode, 250 Hz), four 875 nm LEDs (average power
of each diode, 17.5 mW), four 640 nm LEDs (average
power of each diode, 15 mW), and a static magnetic field
(35 mT) manufactured by Multi Radiance Medical
(Solon, OH - USA). Considering the large irradiation
area used in the present project, the use of diode clusters
was essential for the application of PBMT/sMF; the clus-
ter was circular and had a total irradiation area of 20
cm2.
The dose for active PBMT/sMF was 30 J per area (228
s of irradiation in each area) [14], 510 J of irradiated en-
ergy per lower limb [18, 25, 31], and 1020 J of total irra-
diated energy [18, 25, 31]. The dose used at each site
was previously tested and optimised by our research
group using the same PBMT/sMF device and demon-
strated favourable results in terms of enhancing per-
formance and muscle recovery [14]. Furthermore, the
irradiation sites were also previously optimised by our
research group [18, 25, 31]. The complete description of
PBMT/sMF parameters is presented in Table 1.
Statistical analysis
The primary outcome of this study was time until ex-
haustion, obtained from the progressive treadmill test.
The secondary outcomes were VO2max in relation to
body mass and body fat percentage. The intention-to-
treat analysis was followed a priori, and all data were
analysed by a blinded researcher who was not involved
in the data collection. The findings were tested for nor-
mality using the Shapiro–Wilk test and were determined
to have a normal distribution. Data were expressed as
the mean and standard deviation and were analysed by
Fig. 2 a: Treatment sites at knee extensor muscles b: Treatment sites
at knee-flexor and ankle plantar-flexor muscles
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Table 1 Parameters for PBMT/sMF
Number of lasers 4 Super-pulsed (infrared)
Wavelength (nm) 905 (±1)
Frequency (Hz) 250
Peak power (W) - each 12.5
Average mean optical output (mW) – each 0.3125
Power density (mW/cm2) - each 0.71
Energy density (J/cm2) - each 0.162
Dose (J) - each 0.07125
Spot size of laser (cm2) - each 0.44
Number of red LEDs 4 Red
Wavelength of red LEDs (nm) 640 (±10)
Frequency (Hz) 2
Average optical output (mW) - each 15
Power density (mW/cm2) - each 16.66
Energy density (J/cm2) - each 3.8
Dose (J) - each 3.42
Spot size of red LED (cm2) - each 0.9
Number of infrared LEDs 4 Infrared
Wavelength of infrared LEDs (nm) 875 (±10)
Frequency (Hz) 16
Average optical output (mW) - each 17.5
Power density (mW/cm2) - each 19.44
Energy density (J/cm2) - each 4.43
Dose (J) - each 3.99
Spot size of LED (cm2) - each 0.9
Magnetic Field (mT) 35
Irradiation time per site (sec) 228
Total dose per site (J) 30
Total dose applied per lower limb (J) 510
Aperture of device (cm2) 20
Application mode Cluster probe held stationary in skin contact with a 90-degree angle and slight pressure
Table 2 Participants’ characteristics in absolute values
PBMT/sMF + PBMT/sMF PBMT/sMF + Placebo Placebo + PBMT/sMF Placebo + Placebo
Age (years) 24.79 ± 5.22 23.82 ± 4.29 23.81 ± 6.01 28.83 ± 5.52
Body mass (kg) 78.09 ± 16.49 73.71 ± 14.33 71.24 ± 13.50 79.99 ± 12.12
Height (cm) 174.71 ± 7.32 175.94 ± 4.94 173.88 ± 6.67 173.17 ± 7.59
Body mass indexa 25.55 ± 5.16 23.78 ± 4.43 23.52 ± 4.10 26.62 ± 3.17
Heart rate (beats per minute) 82.21 ± 11.34 80.65 ± 13.93 84.13 ± 14.12 84.08 ± 11.14
Systolic blood pressure (mmHg) 114.29 ± 5.56 117.07 ± 14.04 110.00 ± 8.94 120.00 ± 18.59
Diastolic blood pressure (mmHg) 80.00 ± 5.55 81.18 ± 7.81 77.50 ± 7.75 85.00 ± 13.82
a Calculated as kg/m2; VO2 max: oxygen uptake. Data is expressed in average and standard deviation (±)
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two-way repeated measures analysis of variance
(ANOVA, time vs experimental group) with post-hoc
Bonferroni correction. Data were also analysed in terms
of the absolute values and the percentage of change
based on the values established at baseline. The signifi-
cance level was set at p < 0.05. In the graphs, data are
expressed as the mean and standard error of the mean
(SEM).
Results
All 60 participants completed the full 16-week study;
there were no dropouts and there were no adverse ef-
fects reported. The characteristics of the volunteers are
summarised in Table 2. Statistical analysis revealed that
there were no significant differences (p > 0.05) between
the volunteers from the four experimental groups with
respect to the participants’ characteristics.
Table 3 shows the results of the progressive cardiopul-
monary test in absolute values for the different variables
analysed in all experimental groups of this study. There
were no statistically significant differences in time until
exhaustion or body fat percentage between the groups.
Regarding the VO2max, all groups treated with PBMT/
sMF showed an increase in VO2max over time when
compared to the Placebo+Placebo group. This difference
was statistically significant in the PBMT/sMF + PBMT/
sMF group (p < 0.05, p < 0.05, p < 0.05, and p < 0.01) and
the PBMT/sMF + Placebo group (p < 0.01, p < 0.001, p <
0.001, and p < 0.05) at all experimental time-points (4th,
8th, 12th, and 16th weeks, respectively).
With respect to the time until exhaustion, Fig. 3 shows
the percentage of change in the evaluated time-points.
The PBMT/sMF + PBMT/sMF group showed a statisti-
cally significant difference (p < 0.05, p < 0.0001, p <
0.0001, and p < 0.0001) at all experimental time-points
(4th, 8th, 12th, and 16th week, respectively) when com-
pared to the Placebo+Placebo group. In the detraining
period (16th week), the PBMT/sMF + PBMT/sMF group
also showed a statistically significant difference (p < 0.05)
compared to the PBMT/sMF + Placebo group. More-
over, the group treated with PBMT/sMF only in the
training period (PBMT/sMF + Placebo) or in the detrain-
ing period (Placebo+PBMT/sMF), showed a statistically
significant difference (p < 0.01 and p < 0.05, respectively)
in the percentage of change of time until exhaustion
when compared to the placebo.
Figure 4 graphically represents the percentage of
change in VO2max in relation to body mass in the study
participants. The PBMT/sMF + PBMT/sMF group
showed a statistically significant difference (p < 0.0001,
p < 0.0001, p < 0.0001, and p < 0.0001) when compared
to the Placebo +Placebo group, at all experimental time-
points (4th, 8th, 12th, and 16th week, respectively). In
the 16th week, the PBMT/sMF + PBMT/sMF group also
presented a statistically significant difference compared
to the Placebo+PBMT/sMF group (p < 0.0001) and the
PBMT/sMF + Placebo group (p < 0.001). The groups that
received PBMT/sMF only in the training period (PBMT/
sMF + Placebo) or in the detraining period (Place-
bo+PBMT/sMF), also presented a statistically significant
Table 3 Progressive endurance test variables in absolute values
Baseline 4 weeks 8 weeks 12 weeks 16 weeks
Time until exhaustion (sec)
PBMT/sMF + PBMT/sMF 767.29 ± 77.58 887.86 ± 81.37 921.21 ± 101.07 986.86 ± 125.53 932.57 ± 110.46
PBMT/sMF + Placebo 812.53 ± 121.46 934.35 ± 134.16 980.24 ± 149.28 1025.65 ± 165.58 915.53 ± 147.63
Placebo + PBMT/sMF 853.54 ± 146.12 906.5 ± 167.54 949.25 ± 176.76 961 ± 153.46 940.06 ± 142.37
Placebo + Placebo 801.67 ± 122.49 855.83 ± 134.66 853 ± 119.39 892.67 ± 155.03 823.08 ± 160.85
VO2 max (mL/kg/min)
PBMT/sMF + PBMT/sMF 21.94 ± 2.71 30.81 ± 4.38* 30.87 ± 4.49* 30.64 ± 4.98* 30.26 ± 5.42**
PBMT/sMF + Placebo 24.91 ± 6.08 32.06 ± 8.53** 33.48 ± 7.97*** 33.34 ± 9.13*** 29.46 ± 8.16*
Placebo + PBMT/sMF 24.61 ± 6.14 26.93 ± 7.25 28.27 ± 6.41 27.4 ± 5.51 28.15 ± 5.44
Placebo + Placebo 22.06 ± 5.12 24.68 ± 4.96 24.89 ± 5.60 24.34 ± 5.24 22.38 ± 5.31
Fat percentage
PBMT/sMF + PBMT/sMF 24.55 ± 10.64 22.61 ± 9.07 22.3 ± 8.74 21.59 ± 9.58 20.84 ± 8.65
PBMT/sMF + Placebo 26.16 ± 6.46 25.39 ± 7.31 25.19 ± 6.7 24.85 ± 7.21 25.2 ± 7.98
Placebo + PBMT/sMF 18.8 ± 10.39 17.83 ± 10.00 17.62 ± 10.00 16.96 ± 9.14 17.24 ± 9.19
Placebo + Placebo 21.05 ± 9.60 20.29 ± 9.24 19.91 ± 8.89 19.43 ± 8.56 19.13 ± 8.53
Data are expressed as means and standard deviations (±). VO2 max: maximum oxygen uptake.
* indicates a statistically significant difference compared to
Placebo+Placebo (p < 0.05), ** indicates a statistically significant difference compared to Placebo+Placebo (p < 0.01), *** indicates a statistically significant difference
compared to Placebo+Placebo (p < 0.001)
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difference (p < 0.01 and p < 0.05, respectively) compared
to the Placebo+Placebo group at the 16th week.
Figure 5 shows the percentage of change in body
fat percentage throughout the study. Only the group
treated with PBMT/sMF throughout the whole study
(PBMT/sMF + PBMT/sMF) demonstrated a percentage
of change statistically superior (p < 0.05) in body fat
mass compared to the Placebo+Placebo group, at the
16th week. There were no significant differences in
the other experimental groups or time-points tested.
Discussion
It is important to highlight that this was the first study
to evaluate the effects of PBMT and sMF (PBMT/sMF)
in the detraining period after aerobic training. In the
present study, the application of PBMT/sMF before and
after each training session, 3 times a week for 12 weeks,
led to a statistically significant increase in the absolute
values of VO2max at all evaluated time-points for the
PBMT/sMF + PBMT/sMF group and the PBMT/sMF +
Placebo group compared to the Placebo+Placebo group.
Fig. 3 Percentage of change in time to exhaustion. The data are presented in mean and SEM. * indicates statistical significance of p < 0.05
compared to Placebo+Placebo; ** indicates statistical significance of p < 0.01 compared to Placebo+Placebo; **** indicates statistical significance
of p < 0.0001 compared to Placebo+Placebo; ø indicates statistical significance of p < 0.05 compared to Placebo+PBMT/sMF; øø indicates statistical
significance of p < 0.01 compared to Placebo+PBMT/sMF; øøøø indicates statistical significance of p < 0.0001 compared to Placebo+PBMT/sMF; and
# indicates statistical significance of p < 0.05 compared to PBMT/sMF + Placebo
Fig. 4 Percentage of change in relative maximum oxygen uptake. The data are presented in mean and SEM. * indicates statistical significance of
p < 0.05 compared to Placebo+Placebo; ** indicates statistical significance of p < 0.01 compared to Placebo+Placebo; **** indicates statistical
significance of p < 0.0001 compared to Placebo+Placebo; øøø indicates statistical significance of p < 0.001 compared to Placebo+PBMT/sMF; øøøø
indicates statistical significance of p < 0.0001 compared to Placebo+PBMT/sMF; ### indicates statistical significance of p < 0.001 compared
to PBMT/sMF + Placebo
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These positive results corroborate previous findings by
our research group [25] as well as those reported by
Paolillo et al. [34, 35]. Moreover, we observed that in the
final training phase (12th week), PBMT/sMF improved
the percentage of change of VO2max in 40.02% and time
until exhaustion in 28.62%. Again, our results further
validate the findings of Miranda et al. [25] and Paolillo
et al. [25, 34, 35], thereby increasing the body of evi-
dence supporting the benefits of PBMT in association
with aerobic training.
As previously mentioned, the main goal of this study
was to investigate the effects of PBMT/sMF during a 4-
week period without physical activity. At the end of this
period, the group that received PBMT/sMF throughout
the whole study (PBMT/sMF + PBMT/sMF group)
showed a statistically significant difference in the abso-
lute values (p < 0.01) of VO2max compared to the Place-
bo+Placebo group. Interestingly, PBMT/sMF applied
only during the training phase (PBMT/sMF + Placebo)
also led to a statistically significant increase (p < 0.05) in
the absolute values of VO2max compared to the absolute
values observed in the Placebo+Placebo group in the
16th week.
Previous studies have shown that a period of physical
inactivity, specifically between 2 to 4 weeks [8], can lead
to significant losses in aerobic capacity [5, 8]. In our
study, we also observed a decrease in percentage of
change of VO2max in the Placebo+Placebo and PBMT/
sMF + Placebo groups during the detraining period (16th
week) compared to the training period (12th week). Des-
pite the lack of consensus regarding the magnitude of
the loss of aerobic capacity provoked by a period of no
physical activity, we believe that decreases in percentage
of change of VO2max observed in the Placebo+Placebo
and PBMT/sMF + Placebo groups are mainly related to
the initial level of physical fitness of the practitioners as
well as the duration of the detraining period, as de-
scribed in the literature [8].
Similarly, the percentage of change in time until ex-
haustion was significantly higher in the PBMT/sMF +
PBMT/sMF group than in the Placebo+Placebo group
(21.55% versus 2.46%) in the 16th week. Moreover, the
Placebo+PBMT/sMF group showed better results than
the Placebo+Placebo group (10.7% versus 2.46%) in the
16th week. The group that received PBMT/sMF
throughout the entire training and detraining periods
also showed an increased change in percentage of fat.
However, this same group showed a statistically signifi-
cant decrease in this percentage, in relation to the Place-
bo+Placebo group, only in the detraining period (16th
week). These findings allow us to infer that the applica-
tion of PBMT/sMF throughout the whole study aided in
reducing the body fat of the participants, even during a
period without training. Similar findings were previously
presented with the use of PBMT/sMF applied before
and after aerobic training sessions [25]. These findings
reiterate the increased effectiveness of PBMT/sMF when
applied in both training and detraining periods.
The positive results obtained from the use of PBMT/
sMF can be attributed to its ergogenic effects on aerobic
training, similar to the findings of Miranda et al. [25].
Moreover, the parameters used for irradiation in the
present study are in line with those recently recom-
mended by Leal-Junior et al. [10]. The establishment of
optimised parameters is paramount for the effectiveness
of PBMT/sMF since, in addition to the dose, the moment
to perform the treatment and application sites should also
be considered for therapy optimisation [36]. Given the im-
portance of these factors, the protocol for irradiation
followed the same parameters as those previously tested
Fig. 5 Percentage of change in body fat. The data are presented in mean and SEM. * indicates statistical significance of p < 0.05 compared
to Placebo+Placebo
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by Miranda et al. [25], which showed positive effects for
the percentage of change in VO2max, time until exhaus-
tion, and body fat.
We believe that our findings are of great importance,
especially in both rehabilitation and sports scenarios. It
is well-known how difficult it is for elite athletes to
maintain their performance levels, especially due to fre-
quent injuries and consequent removal from their train-
ing routine. In this regard, our findings suggest that
PBMT/sMF can be an efficient alternative to physical
trainers, athletes, and coaches in periods where aerobic
training is interrupted.
Our findings may also bring up the question of
whether PBMT/sMF is an acceptable technique for
training and detraining in competitive and professional
sports. The current version of the World Anti-Doping
Code, published by the World Anti-Doping Agency
(WADA) in 2015 [37], states that a substance or method
can be considered as doping if two of the following three
criteria are fulfilled: ‘1 - Medical or other scientific evi-
dence, pharmacological effect or experience that the
substance or method, alone or in combination with
other substances or methods, has the potential to en-
hance or enhances sport performance; 2 - Medical or
other scientific evidence, pharmacological effect or ex-
perience that the use of the substance or method repre-
sents an actual or potential health risk to the athlete;
and 3 - WADA’s determination that the use of the sub-
stance or method violates the spirit of sport described in
the introduction to the code’. Furthermore, WADA also
states that ‘A substance or method shall also be included
on the Prohibited List if WADA determines there is
medical or other scientific evidence, pharmacological ef-
fect or experience that the substance or method has the
potential to mask the Use of other Prohibited Substances
or Prohibited Methods’.
However, since, as far as we know, PBMT/sMF does
not have side effects or potential health risks, it is likely
not fulfilling criterion number 2. Moreover, as the last
criterion is more political than scientific, the decision
about whether PBMT/sMF use should be included in
the prohibited list of WADA is for the members of the
executive board committee to decide.
A limitation of our study is that we did not investi-
gate the mechanisms of action behind the positive ef-
fects presented by PBMT/sMF, which limits us to
provide mechanistic insights related to the ergogenic
effects of the therapy. Despite the wide number of re-
ports regarding the modulatory effects of PBMT/sMF
in cellular metabolism [11, 12, 23] and on the partial
pressure of oxygen and oxygen saturation in peripheral
blood cells [26], we believe that further research should
focus on the mechanisms of action behind the ergo-
genic effects of PBMT/sMF in humans. A second
limitation of this study is that we did not monitor the
habitual activity of our participants during detraining,
which should also be considered in further research.
The last limitation of this study is that only 4 weeks of
detraining after 12 weeks of aerobic endurance training
were analysed; however, the attenuation of the losses
due to the interruption of physical activity is of great
value, both for professional and amateur athletes. These
benefits can also be transferred to several different sce-
narios, such as individuals affected by illness and those
who are bedridden or unable to perform physical exer-
cises for rehabilitation.
Conclusions
In the present study, the use of PBMT/sMF was able to
potentiate the effects of aerobic training and reduce
losses caused by the detraining period. Therefore, we be-
lieve that the results of the study are relevant and sug-
gest a new perspective on the use of PBMT/sMF by
recognising its effectiveness in maintaining the benefits
obtained after aerobic training, during the detraining
period.
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